Literature DB >> 16954473

Prospective breast cancer risk prediction model for women undergoing screening mammography.

William E Barlow1, Emily White, Rachel Ballard-Barbash, Pamela M Vacek, Linda Titus-Ernstoff, Patricia A Carney, Jeffrey A Tice, Diana S M Buist, Berta M Geller, Robert Rosenberg, Bonnie C Yankaskas, Karla Kerlikowske.   

Abstract

BACKGROUND: Risk prediction models for breast cancer can be improved by the addition of recently identified risk factors, including breast density and use of hormone therapy. We used prospective risk information to predict a diagnosis of breast cancer in a cohort of 1 million women undergoing screening mammography.
METHODS: There were 2,392,998 eligible screening mammograms from women without previously diagnosed breast cancer who had had a prior mammogram in the preceding 5 years. Within 1 year of the screening mammogram, 11,638 women were diagnosed with breast cancer. Separate logistic regression risk models were constructed for premenopausal and postmenopausal examinations by use of a stringent (P<.0001) criterion for the inclusion of risk factors. Risk models were constructed with 75% of the data and validated with the remaining 25%. Concordance of the predicted with the observed outcomes was assessed by a concordance (c) statistic after logistic regression model fit. All statistical tests were two-sided.
RESULTS: Statistically significant risk factors for breast cancer diagnosis among premenopausal women included age, breast density, family history of breast cancer, and a prior breast procedure. For postmenopausal women, the statistically significant factors included age, breast density, race, ethnicity, family history of breast cancer, a prior breast procedure, body mass index, natural menopause, hormone therapy, and a prior false-positive mammogram. The model may identify high-risk women better than the Gail model, although predictive accuracy was only moderate. The c statistics were 0.631 (95% confidence interval [CI] = 0.618 to 0.644) for premenopausal women and 0.624 (95% CI = 0.619 to 0.630) for postmenopausal women.
CONCLUSION: Breast density is a strong additional risk factor for breast cancer, although it is unknown whether reduction in breast density would reduce risk. Our risk model may be able to identify women at high risk for breast cancer for preventive interventions or more intensive surveillance.

Entities:  

Mesh:

Year:  2006        PMID: 16954473     DOI: 10.1093/jnci/djj331

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  165 in total

1.  Mammographic density and risk of breast cancer by adiposity: an analysis of four case-control studies.

Authors:  Shannon M Conroy; Christy G Woolcott; Karin R Koga; Celia Byrne; Chisato Nagata; Giske Ursin; Celine M Vachon; Martin J Yaffe; Ian Pagano; Gertraud Maskarinec
Journal:  Int J Cancer       Date:  2011-09-17       Impact factor: 7.396

Review 2.  Clinical and epidemiological issues in mammographic density.

Authors:  Valentina Assi; Jane Warwick; Jack Cuzick; Stephen W Duffy
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

3.  Effects of exposure equalization on image signal-to-noise ratios in digital mammography: a simulation study with an anthropomorphic breast phantom.

Authors:  Xinming Liu; Chao-Jen Lai; Gary J Whitman; William R Geiser; Youtao Shen; Ying Yi; Chris C Shaw
Journal:  Med Phys       Date:  2011-12       Impact factor: 4.071

4.  A novel automated mammographic density measure and breast cancer risk.

Authors:  John J Heine; Christopher G Scott; Thomas A Sellers; Kathleen R Brandt; Daniel J Serie; Fang-Fang Wu; Marilyn J Morton; Beth A Schueler; Fergus J Couch; Janet E Olson; V Shane Pankratz; Celine M Vachon
Journal:  J Natl Cancer Inst       Date:  2012-07-03       Impact factor: 13.506

5.  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Authors:  Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

6.  Quantra™ should be considered a tool for two-grade scale mammographic breast density classification.

Authors:  Ernest U Ekpo; Mark F McEntee; Mary Rickard; Patrick C Brennan; Jyotsna Kunduri; Delgermaa Demchig; Claudia Mello-Thoms
Journal:  Br J Radiol       Date:  2016-02-16       Impact factor: 3.039

Review 7.  Risk assessment models to estimate cancer probabilities.

Authors:  Constance M Johnson; Derek Smolenski
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

8.  American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Authors:  Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

9.  Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Authors:  Brian L Sprague; Natasha K Stout; Clyde Schechter; Nicolien T van Ravesteyn; Mucahit Cevik; Oguzhan Alagoz; Christoph I Lee; Jeroen J van den Broek; Diana L Miglioretti; Jeanne S Mandelblatt; Harry J de Koning; Karla Kerlikowske; Constance D Lehman; Anna N A Tosteson
Journal:  Ann Intern Med       Date:  2015-02-03       Impact factor: 25.391

10.  Breast cancer risk prediction and mammography biopsy decisions: a model-based study.

Authors:  Katrina Armstrong; Elizabeth A Handorf; Jinbo Chen; Mirar N Bristol Demeter
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.